TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05664061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals
Description: twice daily inhalation throughout the treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
Description: twice daily inhalation throughout the treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily inhalation throughout the treatment period
Study: NCT06597435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine pouch
Description: Participants will self-administer an experimenter-provided nicotine pouch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine pouch
Description: Participants will self-administer an experimenter-provided nicotine pouch
Study: NCT06058156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444656 (KT-474)
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444656 (KT-474)
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444656 (KT-474)
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT06316362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOF lipid 20%
Description: SMOF 20%; a blend of (soybean oil, medium chain triglycerides, olive and fish oil) is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment for carbamazepine toxicity
Description: Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg).~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube
Study: NCT06597435

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine pouch
Description: Participants will self-administer an experimenter-provided nicotine pouch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine pouch
Description: Participants will self-administer an experimenter-provided nicotine pouch
Study: NCT04903158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test SHR3680 tablets
Description: Subjects receiving a single oral dose of SHR3680 tablets with 240mg (80mg\*3)

Intervention type: DRUG
Group type: OTHER
Intervention: reference SHR3680 tablets
Description: subjects receiving a single oral dose of SHR3680 tablets with 240mg (100mg\*2+20mg\*2).
Study: NCT05774938

Intervention type: PROCEDURE
Intervention: Standard Endovascular aneurysm repair (sEVAR)
Description: Standard EVAR treatment with Medtronic Endurant IIs (Medtronic, Inc. - Minneapolis, Minnesota), Gore Excluder AAA (W. L. Gore \& Associates, Inc. - Newark, Delaware), Gore Excluder Conformable AAA (W. L. Gore \& Associates, Inc. - Newark, Delaware), Cook Zenith Flex (Cook Medical, Inc. - Bloomington, Indiana).

Intervention type: PROCEDURE
Intervention: Complex Endovascular Aneurysm Repair (cEVAR)
Description: Complex EVAR treatment with custom made devices (CMD's) from Cook Medical (Cook Medical, Inc. - Bloomington, Indiana) including fenestrated or branched devices or off-the-shelf T-branch device (Cook Medical, Inc. - Bloomington, Indiana).
Study: NCT06378593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3HP-2827
Description: 3HP-2827 will be administered orally once daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3HP-2827
Description: 3HP-2827 will be administered orally once daily in 28-day cycles.
Study: NCT06537427

Intervention type: OTHER
Intervention: Data collection
Description: The data to be collected are the following:~* Demographic data: gender and age of the patient at diagnosis of SCI;~* Drug assumption and drug abuse at the time of SCI;~* A complete assessment of patients' comorbidities;~* Complete neurological examination on admission and at 6-8 months follow-up according to ASIA protocol;~* Neuro-radiological data: spinal CT and MRI performed within 48 hours of admission to document the type, level and extent of the lesion of the spine and the spinal cord;~* CSF pressure, chemical and biological markers;~* Serum chemical and biological markers;~* Data coming from surgical procedure: type of decompression, type of stabilization, extension of the stabilization, surgical approach, staged surgery, timing of surgery, length of surgery, eventual intraoperative, postoperative or long-term surgical-related complications \[13\];~* Data on hospitalization: length of stay, hospital-acquired infections, any adverse event occurred during hospitalisation.

Intervention type: OTHER
Intervention: Data collection
Description: The data to be collected are the following:~* Demographic data: gender and age of the patient at diagnosis of SCI;~* Drug assumption and drug abuse at the time of SCI;~* A complete assessment of patients' comorbidities;~* Complete neurological examination on admission and at 6-8 months follow-up according to ASIA protocol;~* Neuro-radiological data: spinal CT and MRI performed within 48 hours of admission to document the type, level and extent of the lesion of the spine and the spinal cord;~* CSF pressure, chemical and biological markers;~* Serum chemical and biological markers;~* Data coming from surgical procedure: type of decompression, type of stabilization, extension of the stabilization, surgical approach, staged surgery, timing of surgery, length of surgery, eventual intraoperative, postoperative or long-term surgical-related complications \[13\];~* Data on hospitalization: length of stay, hospital-acquired infections, any adverse event occurred during hospitalisation.
Study: NCT06128772

Intervention type: OTHER
Group type: OTHER
Intervention: Battlefield Acupuncture
Description: 5 points of acupuncture treatment in each ear weekly for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Battlefield Acupuncture
Description: 5 points of acupuncture treatment in each ear weekly for 8 weeks
Study: NCT05879536

Intervention type: DRUG
Intervention: Tramadol-ondansetron continuous infusion
Description: Analgesia strategy determined by routine use according to protocols, without investigator intervention.

Intervention type: DRUG
Intervention: Ropivacaine via epidural catheter
Description: Analgesia strategy determined by routine use according to protocols, without investigator intervention.
Study: NCT05715411

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with light therapy glasses
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light therapy with light therapy glasses
Description: light therapy
Study: NCT06162949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: An antibiotic of penicillins antibiotic group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: An antibiotic of penicillins antibiotic group
Study: NCT06355037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: quercetin 1000mg d1-d3, qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 50mg d1-d3, qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Description: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Study: NCT06690996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered IV
Study: NCT06162949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: An antibiotic of macrolide group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: An antibiotic of macrolide group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: An acid suppressor therapy that blocks the proton pump.
Study: NCT06131814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 groups
Description: up 5 times repetition twice a week in first 4 week and then progress to 10 times repetition twice a week from 5-8th week of session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 groups
Description: up 5 times repetition twice a week in first 4 week and then progress to 10 times repetition twice a week from 5-8th week of session
Study: NCT06577129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ladder training
Description: Players exercised three times a week for sixty minutes apiece on a ladder for eight weeks. The drills were divided into three categories: steady state drills, burst drills, and elastic reaction drills. While steady state training focused on agility and endurance, burst drills were more focused on fast foot movement. Elastic response drills targeted the reactive speed components of the lower leg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric training
Description: For eight weeks, the players performed a 60-minute plyometric training program three times a week. A fifteen-minute warm-up, stretching, and jogging session comes after the thirty minutes of plyometric training. The cool-down consists of fifteen minutes of light running and stretching.
Study: NCT06690996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4005130
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT05260801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Lighting
Description: The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Lighting
Description: The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Lighting
Description: The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Lighting
Description: The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
Study: NCT05706805

Intervention type: DEVICE
Intervention: Naviscore
Description: Patients in whom treatment with (Naviscore) has been attempted
Study: NCT06267053

Intervention type: DIAGNOSTIC_TEST
Intervention: Direct digital radiography
Description: All the participants had anterior posterior and lateral knee xray taken within 3 months of diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: 25-OH Vitamin D
Description: All the participants had serum 25-OH Vitamin D levels measured from venous blood within 30 days of diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin B12
Description: All the participants had serum Vitamin B12 levels measured from venous blood within 30 days of diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Folic acid
Description: All the participants had serum folic acid levels measured from venous blood within 30 days of diagnosis
Study: NCT06690996

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05877820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral tablet
Study: NCT04749186

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compuflo Epidural Training Instrument
Description: The intervention will consist of a Structured Didactic Model. It will include the following: two standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
Study: NCT04999228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab will be administered intravenously at a dose of 5 mg/kg for 0, 2, and 6 weeks, then every 8 weeks for 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroid will be given at a dose of 1-2mg/kg/day (maximum 60 mg/kg/day),oral or intravenously for 12 to 14 weeks.
Study: NCT05485181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spiritual Intervention
Description: The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spiritual Intervention
Description: The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.
Study: NCT06503744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation
Description: ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: ablation
Study: NCT05261425

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl buried
Description: Participants randomized to this group will receive the Monocryl (suture) buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon (FDA Approved) not buried
Description: Participants randomized to this group will receive the Nylon (FDA Approved) (suture) not buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
Study: NCT05489484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Shoulder Collagen Medical Device
Description: Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).~Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.~Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.~MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis.
Study: NCT06544018

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Genetic analysis of NLRP3
Description: Blood test for genetic analysis of NLRP3

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetic analysis of NLRP3
Description: Blood test for genetic analysis of NLRP3

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Circadian rhythm measurement
Description: Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circadian rhythm measurement
Description: Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saliva sampling
Description: Saliva sampling for salivary melatonin determination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saliva sampling
Description: Saliva sampling for salivary melatonin determination
Study: NCT06714344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KITGuideMe: W61-MD41-AIT, version 1.0.0
Description: We are planning to conduct a prospective, 1:1 randomized study within the HM program.~Randomization occurs at the level of network physicians. Network physicians participating in the study are randomly assigned to either the AMPEL group (access to the module) or the non-AMPEL group (no access to the module) using a permuted block randomization scheme to ensure that there are the same number of patients in each study arm. Logical checks within the module ensure that once a network physician is assigned to an arm, he or she remains in that arm for the remainder of the stud
Study: NCT06721039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral QL block
Description: sonovisible block needle will be inserted under ultra-sonographic monitoring between the iliac wing and rib at the midaxillary line for the TQL block in the lateral decubitus positioning of the patient. The space between the quadratus lumborum and psoas major muscles will be visualized with Ultrasound Guided and 0.25% bupivacaine will be injected after visualization of the tip of the needle reaching the plane, 2ml of anaesthetic solution will be instilled to view the hydro dissection, confirming the correct placement. Following this, the total volume of 40 ml of 0.25% bupivacaine will be instilled, creating a meniscus between the planes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal and port sites infiltration
Description: with 40 ml of 0.25% bupivacaine will be injected under the direct vision into the hepato-diaphragmatic space, near and above the hepato-duodenal ligament and above the gall bladder also injected at the port sites at the end of operation before removal of the probes
Study: NCT06544018

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire
Description: Questionnaire to determine chronotype

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaire to determine chronotype

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIDAI score
Description: Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: 1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18.~2. Molecular characterization of circadian clock signaling pathways

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: 1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18.~2. Molecular characterization of circadian clock signaling pathways
Study: NCT04825691

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry of prostate biopsy
Description: Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions
Study: NCT05510713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis Catheter
Description: We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous